-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-07-15
Values as of: 2019-07-15
The investment seeks to track the investment results of Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying fund measures the performance of the pharmaceuticals sector of the U.S. equity market and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
Company Website : www.ishares.com
Currency: USD
Country : USA
Inception Date: 01/05/2006
Primary Benchmark: DJ US Select Pharms TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.44%
Management Expense Ratio: 0.42 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| LLY | Eli Lilly and Company | 23.04 % |
| JNJ | Johnson & Johnson | 22.39 % |
| MRK | Merck & Company Inc | 4.83 % |
| PFE | Pfizer Inc | 4.59 % |
| RPRX | Royalty Pharma Plc | 4.52 % |
| VTRS | Viatris Inc | 4.51 % |
| BMY | Bristol-Myers Squibb Company | 4.51 % |
| CTLT | Catalent Inc | 4.23 % |
| ZTS | Zoetis Inc | 4.22 % |
| ELAN | Elanco Animal Health | 3.14 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| SOJE | SOJE | 0.00 % |
+0.07 (+0.37%) |
USD 65.72B |
| JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.12 (-0.22%) |
USD 32.78B |
| LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.28%) |
USD 32.52B |
| DTB | DTB | 0.00 % |
+0.21 (+1.12%) |
USD 26.58B |
| DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.17 (-0.56%) |
USD 26.11B |
| JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
+0.02 (+0.04%) |
USD 22.47B |
| SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
| TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.20 (-0.64%) |
USD 16.23B |
| DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
-0.13 (-0.34%) |
USD 10.15B |
| AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
-0.83 (-0.95%) |
USD 10.05B |
N/A
| Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 4.72% | 25% | F | 27% | F | ||
| Dividend Return | 0.78% | 31% | F | 21% | F | ||
| Total Return | 5.50% | 24% | F | 26% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -7.31% | 20% | F | 33% | F | ||
| Dividend Return | 1.16% | 29% | F | 20% | F | ||
| Total Return | -6.15% | 20% | F | 31% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 10.44% | 59% | D- | 61% | D- | ||
| Dividend Return | 6.37% | 29% | F | 22% | F | ||
| Total Return | 16.80% | 52% | F | 48% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.76% | 32% | F | 45% | F | ||
| Dividend Return | 1.88% | 14% | F | 40% | F | ||
| Total Return | 1.11% | 56% | F | 29% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 12.10% | 57% | F | 81% | B- | ||
| Risk Adjusted Return | 15.51% | 18% | F | 44% | F | ||
| Market Capitalization | 0.69B | 66% | D+ | 38% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
